Trial Profile

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aripiprazole (Primary)
Indications Schizophrenia
Focus Registrational; Therapeutic Use
Acronyms ASPIRE; ASPIRE OPEN-LABEL
Sponsors Otsuka Pharmaceutical Development & Commercialization

Most Recent Events

21 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
07 May 2013 Planned End Date changed from 1 Sep 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
14 Jun 2012 Planned number of patients changed from 800 to 1224 as reported by ClinicalTrials.gov record (parent trial: NCT00731549).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com